11:45 AM EST - Antibe Therapeutics Inc. : Announced the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. for the Canadian rights for Induce’s URIST™ biological product for dental and craniofacial applications. URIST™ is a novel bone graft substitute that contains bone morphogenetic protein-2 (BMP), and is being developed as a means of promoting the regeneration of bone following dental and oral maxillofacial surgery. Antibe Therapeutics Inc.
shares V.ATE are trading unchanged at $0.17.
